• Zum Hauptinhalt springen
  • Zum Footer springen
  • Deutsch - de
  • English - en

    SyNergy - Mu...

    • Über uns
      • Über uns
      • Maßnahmen
      • Mitglieder
      • Cluster Management
      • PhD und Postdoc-Vertreter
      • Wissenschaftlicher Beirat
      • Internationale Kooperationspartner
      • Timeline
      • Pressekit
      • Kontakt
    • Aktuelles
      • News
      • Veranstaltungen
      • Presseecho
      • Stellenausschreibungen
    • Forschung
      • Publikationen
      • Unser Forschungsschwerpunkt
      • Technology Hubs
      • "Research Spotlight"
      • Management von Forschungsdaten
      • Sustainability Initiative
      • Verhaltenskodex
    • Wissenschaft & Gesellschaft
      • Für Schulen und Schüler
      • Öffentliche Veranstaltungen
      • Podcasts
      • Videos
    • Support für Diversity & Equity
      • Newcomer Center
      • Gender Equality Program
      • Early Career Investigator Programm
    1. Home
    2. Aktuelles
    3. News
    4. Amyloidosis triggers age-related oligodendrocyte and myelin damage
    News | 11.07.2024 | Research Spotlight

    Amyloidosis triggers age-related oligodendrocyte and myelin damage

    Age-related myelin damage leads to white matter inflammation, but its impact on chronic neurodegenerative diseases remains unclear. A recent study reveals that amyloidosis alone can cause age-related oligodendrocyte and myelin damage in mouse models of Alzheimer's disease. The research team discovered that CD8 T cells contribute to neurodegenerative diseases associated with amyloidosis by abnormally activating microglia, resulting in myelin damage.

    This is a summary of Kedia, S., Ji, H., Feng, R. et al. T cell-mediated microglial activation triggers myelin pathology in a mouse model of amyloidosis. publishes in Nature Neuroscience (2024). https://doi.org/10.1038/s41593-024-01682-8


    The challenge

    Age-related brain damage induces inflammation and poses a significant risk for various neurodegenerative diseases, including Alzheimer’s disease. However, it is unknown how these age-related changes in myelin and oligodendrocytes contribute to the development of these diseases.


    Our approach

    We used immunohistochemistry and scanning electron microscopy to study oligodendrocyte and myelin changes in a mouse model of Alzheimer’s disease (5xFAD). In 5xFAD mice, we examined increased oligodendrocyte and myelin pathology in both the white and gray matter and detected a small but elevated number of CD8+ T cells. To understand whether CD8+ T cells contribute to oligodendrocyte and myelin responses, we performed antibody mediated CD8+ T cell depletion.


    Our findings

    Our results show that antibody mediated CD8+ T cell depletion rescued oligodendrocyte and myelin damage in 5xFAD mice. Additionally, CD8+ T cell depletion improved spatial learning and memory. To mechanistically understand how CD8+ T cells drive the pathology, we performed single cell RNA sequencing and identified a decrease in a specific microglia cluster enriched in major histocompatibility complex class II (MHCII) genes in CD8+ T cell depleted mice. We observed an upregulation in MHCII+ microglia populations in the vicinity of T cells in both mouse and human autopsy tissue. We further provide evidence that these abnormally activated microglia display myelin damaging activity.


    The implications

    Our study provides mechanistic insights into how T cell mediated neuroinflammation can induce oligodendrocyte and myelin pathology. If these results are further validated in human studies, targeting inflammation to specifically improve oligodendrocyte health could offer significant therapeutic promise for delaying AD.


    Creating SyNergies

    The study, led by SyNergy member Mikael Simons, is a collaboration with SyNergy investigators Arthur Liesz and Martina Schifferer, and LMU, TUM, and DZNE researchers. In future research, we will investigate how tissue-resident CD8 cells, which develop across various neurological diseases, exert their harmful effects and whether these mechanisms are also present in human diseases.

    Teilnehmende Universitäten
     LMU logo in white
     TUM logo in white
    Partnerinstitute
     Logo DZNE in white
    Helmholtz Munich logo in white 
     Logo Max Planck Gesellschaft 

    SyNergy wird von der Deutschen Forschungsgemeinschaft im Rahmen der deutschen Exzellenzstrategie gefördert (EXC 2145 SyNergy - ID 390857198). Die Exzellenzstrategie fördert herausragende Forschung an deutschen Universitäten. 

    Kontakt

    Munich Cluster for Systems Neurology (SyNergy)

    Feodor-Lynen-Str. 17
    81377 Munich
    +49 (0)89 4400-46497
    yüubgDybcјuipxј#JvfulDyztmi
    Anmeldung für Redakteure
    Impressum | Datenschutz